Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ERN1 | O75460 | 2/20 | 0.53 |
| ▸ | TLR2 | O60603 | 1/20 | 0.53 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.53 |
| ▸ | TLR6 | Q9Y2C9 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.47 |
| ▸ | TFEB | P19484 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11323988 | 0.89 | ALDH1A1 (0.53) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| 2-Methoxybenzaldehyde SCHEMBL8469378 | 0.88 | ALDH1A1 (0.66) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| 2-Methoxybenzaldehyde SCHEMBL29358929 | 0.88 | ALDH1A1 (0.66) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| 2-Methoxybenzaldehyde SCHEMBL66490 | 0.88 | ALDH1A1 (0.66) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| 2-Methoxybenzaldehyde SCHEMBL28954369 | 0.86 | ALDH1A1 (0.63) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| 2-Methoxybenzaldehyde SCHEMBL28639538 | 0.86 | ALDH1A1 (0.63) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| 2-Methoxybenzaldehyde SCHEMBL28257560 | 0.86 | ALDH1A1 (0.63) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| 2-Methoxybenzaldehyde SCHEMBL27949860 | 0.86 | ALDH1A1 (0.63) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| 2-Methoxybenzaldehyde SCHEMBL27337621 | 0.86 | ALDH1A1 (0.63) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| 2-Methoxybenzaldehyde SCHEMBL28193905 | 0.86 | LMNA (0.63) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107848990-A | The manufacture method of the side chain precursor of taxol and Docetaxel | 万代忠胜 | 2018-03-27 | — | — | CN | disclosed |
| US-8222381-B2 | Derivatives of monosaccharides for drug discovery | ALCHEMIA LIMITED (AU) | 2012-07-17 | — | — | US | disclosed |
| EP-1934388-A1 | METHOD OF DRUG DESIGN | Alchemia Ltd (AU) | 2008-06-25 | — | — | EP | disclosed |
| EP-1797428-A1 | SELECTIVE INHIBITORS | Alchemia Pty Ltd (AU) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007038829-A1 | METHOD OF DRUG DESIGN | ALCHEMIA LTD (AU) | 2007-04-12 | — | — | WO | disclosed |
| US-20060167237-A1 | Derivatives of monosaccharides for drug discovery | ALCHEMIA LIMITED (AU) | 2006-07-27 | — | — | US | disclosed |
| WO-2006037159-A1 | SELECTIVE INHIBITORS | ALCHEMIA LIMITED (AU) | 2006-04-13 | — | — | WO | disclosed |
| EP-1539780-A1 | DERIVATIVES OF MONOSACCHARIDES FOR DRUG DISCOVERY | Alchemia Limited (AU) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004014929-A1 | DERIVATIVES OF MONOSACCHARIDES FOR DRUG DISCOVERY | ALCHEMIA LIMITED (AU) | 2004-02-19 | — | — | WO | disclosed |
| US-6607655-B1 | Electrode and a counter-electrode are known, whereby the electrodes are separated form one another by a capillary gap. Such reactors do not comprise a homogeneous flow rate distribution in the capillary gap which can thus lead to a | INSTITUT FUR MIKROTECHNIK MAINZ GMBH (DE) | 2003-08-19 | — | — | US | disclosed |
| WO-1997007809-A1 | SULFATED DISACCHARIDE INHIBITORS OF SELECTINS METHODS FOR SYNTHESIS AND THERAPEUTIC USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167237-A1 | Derivatives of monosaccharides for drug discovery | FBP1, UGGT1, FUT6 | ALDH1A1 554/4885LMNA 4686/4885CYP1A2 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.